Month: September 2026

• CROSSJECT and BARDA have consolidated the clinical development plan for the pediatric indication of ZEPIZURE®, in alignment with the FDA guidance
• $4.7 million in additional, non-dilutive funding, to cover the planned activities — total BARDA funding for ZEPIZURE® development now $48.0 million
• Contract period of performance extended through June 21, 2030
• The EUA pathway for the adult indication is unaffected: the scope, content and data package of the EUA dossier remain unchanged
  

DIJON, France — September 23rd, 2026 – 19h00 (CEST) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the global specialty pharma company developing needle-free autoinjectors for emergency situations, today announces that CROSSJECT and BARDA have consolidated the clinical development plan for the pediatric indication of ZEPIZURE®, in alignment with the FDA guidance. Under Modification 4 to contract n° 75A50122C00031, BARDA is providing $4.7 million in additional non-dilutive funding to cover this plan and has extended the period of performance through June 21, 2030. Total BARDA funding dedicated to the development of ZEPIZURE® now stands at $48.0 million.

Patrick ALEXANDRE, Chairman of the Company’s Executive Board, said:

« BARDA has agreed to fund, the development that will bring ZENEO® Midazolam to children, and to plan with us through 2030. This action supports the role ZEPIZURE® is expected to play in U.S. emergency preparedness, for adults and for children alike. Our EUA pathway is unchanged, and our teams remain entirely focused on it. »

Pediatric plan designed to align with FDA expectations

The consolidated plan follows ongoing interactions between CROSSJECT, BARDA and the FDA on the pediatric development of ZEPIZURE®. It is funded by BARDA’s additional contribution, and the period of performance has been extended accordingly. Modification 4 also funds a complementary validation campaign, including extended stability, which supports the New Drug Application (NDA), and the long-term management of the product inventory.

No impact on the EUA pathway

The pediatric activities are fully independent from the Emergency Use Authorization submission for the adult indication of ZEPIZURE®. The scope, content and data package of the EUA dossier remain unchanged, and none of the activities funded under Modification 4 is a condition of the EUA.

What Modification 4 does not change

Modification 4 does not alter the EUA pathway, the contracted volumes, or the economics of the acquisition. The contracted acquisition of 306,000 adult and 54,000 pediatric ZENEO® Midazolam autoinjectors for a total of $60,840,000, to be fulfilled upon FDA approval, is unchanged. Modification 4 increases the total potential value of the contract beyond $170 million, should all options be exercised.

        

Forward-Looking Statements by CROSSJECT

This press release may contain forward-looking statements. Although the Company believes that its projections are based on reasonable assumptions, any statements in this press release other than statements of historical fact regarding future events are subject to (i) change without notice, (ii) factors beyond the Company’s control, (iii) the results of clinical studies, (iv) regulatory requirements, (v) increases in production costs, (vi) market access, (vii) reimbursement, (viii) competition, and (ix) potential claims regarding its products or intellectual property. These statements may include, but are not limited to, any statements beginning with, followed by, or including words or phrases such as “objective,” “believe,” “expect,” “aim,” “intend to,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “may have,” “probably,” “should,” “could,” and other words and expressions of similar meaning or used in the negative form. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that may, in certain circumstances, result in material differences between the actual results, performance, or achievements of the Company and those anticipated or expressed explicitly or implicitly by such forward-looking statements. A list and description of these risks, uncertainties, and contingencies are included in the Company’s 2025 Annual Report. Furthermore, these forward-looking statements are valid only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Unless required by law, the Company assumes no obligation to publicly update these forward-looking statements, even if new information becomes available.

This press release was prepared in French and English. In the event of any discrepancies between the two texts, the French version shall prevail.

 

Attachment

• CP-23.09-EN

23 September 2026, Limassol, Cyprus / Ad hoc announcement pursuant to Art. 53 LR

BUSINESS HIGHLIGHTS – FIRST HALF OF 2026

• EPH delivered resilient operating and financial performance in the first half of 2026. Net rental income increased by 1.6% year-on-year to EUR 18.16 million, supported by the quality of the portfolio and stable rental performance.
• At 30 June 2026, EPH’s portfolio comprised ten high-quality office and hotel properties in established locations across Germany, Austria and Switzerland, with a total value of EUR 829.10 million. The stable income base and long-term ownership perspective underpin the portfolio’s resilience.
• EPH reported net profit of EUR 11.66 million, compared with EUR 4.73 million in the first half of 2025. The increase was driven by a EUR 6.18 million revaluation gain on investment properties, primarily from the Austrian portfolio, improved rental performance as mentioned above, and a positive foreign exchange result, compared with a significant foreign exchange loss in the prior-year period.
• EPH continued to invest selectively in the performance and usability of its existing portfolio, focusing on sustainable income, future usability and long-term value preservation.
• At the Trois Couronnes hotel property in Switzerland, the ongoing refurbishment progressed, with construction in progress increasing to EUR 1.82 million at 30 June 2026. The project remains focused on quality, commercial viability and the asset’s long-term positioning.

 FINANCIAL HIGHLIGHTS – FIRST HALF OF 2026

• Total assets amounted to EUR 995.75 million at 30 June 2026, broadly unchanged from EUR 995.89 million at year-end 2025.
• Total equity increased to EUR 525.72 million from EUR 514.22 million at year-end 2025, while net asset value per share rose from EUR 35.31 to EUR 36.10.
• Earnings from operational activity increased to EUR 5.79 million from EUR 5.59 million in the first half of 2025.
• The main factors influencing the Company’s financial performance include:
• An increase in net rental income from EUR 17.88 million in the first half of 2025 to EUR 18.16 million in the first half of 2026.
• A gain on revaluation of investment properties of EUR 6.18 million, compared with a gain of EUR 3.14 million in the first half of 2025. The Austrian investment properties recorded a combined revaluation gain of EUR 5.38 million, while the German investment properties contributed EUR 0.80 million.
• Finance costs decreased slightly from EUR 9.14 million in the first half of 2025 to EUR 8.87 million in the first half of 2026.
• Total borrowings decreased from EUR 440.36 million at year-end 2025 to EUR 426.68 million at 30 June 2026, and the loan-to-value ratio improved from 44% to 43%. In May 2026, EPH repaid the bank loan secured against SALZ 4 ahead of schedule, removing the related bank security and generating a gain of approximately EUR 0.48 million on the early termination of the associated interest rate swap.

SUBSEQUENT EVENT

• After the reporting period, EPH proposed amendments to the terms of its four listed bonds, with a total nominal value of EUR 411.775 million, subject to bondholder approval. The proposed amendments are intended to strengthen liquidity and provide greater financial flexibility for selected investments and development projects. 

OUTLOOK

• EPH remains confident in the long-term fundamentals of its target markets. Demand continues to favour well-located, modern, flexible and efficiently operated buildings.
• EPH will also evaluate acquisition opportunities selectively. Any investment must meet the Company’s requirements for quality, pricing, income potential, financing and risk-adjusted returns. Portfolio growth is not an objective in itself.
• EPH’s portfolio quality, stable income base and long-term ownership perspective provide a solid foundation for sustainable value creation.

 The full Semi-Annual Report 2026, including the Interim Condensed Consolidated Financial Information (unaudited) for EPH, is available on the Company’s website:

EPH SEMI-ANNUAL REPORT 2026

EPH European Property Holdings PLC is an investment company listed on SIX Swiss Exchange. Additional information on EPH European Property Holdings PLC is available by contacting Anna Bernhart Tel: +41 44 503 5400 or at contact@europeanpropertyholdings.com

 

Attachment

• 260923 EPH_HY26_FINAL

Dassault Aviation signs a Cooperation Agreement
with AED Cluster Portugal

(Saint-Cloud, France – Lisbon, Portugal – September 23, 2026) – Dassault Aviation, representing its RAFALE partners, Thales and Safran, signed with AED Cluster Portugal, Portugal’s association for the aeronautics, space and defence industries, a Memorandum of Understanding (MoU) to explore potential areas of cooperation between RAFALE partners and the Portuguese industrial sector, in the context of the Portuguese Air Force’s F-16 fleet renewal.

The signing of this agreement, which took place at the French Embassy in the presence of the Ambassador of the French Republic in Portugal, H.E. Asvazadourian, follows the official submission of a bid for the RAFALE to the Portuguese Government and to the Portuguese Air Force in July 2026.

This MOU demonstrates the commitment of the RAFALE partners already established in the country to build on the existing relationship and to take cooperation with AED and Portuguese industrial partners a step further, in order to boost the Portuguese economy and strengthen the country’s sovereignty.

ABOUT DASSAULT AVIATION:

With over 10,000 military and civil aircraft (including 2,800 Falcons) delivered in more than 90 countries over the past 110 years, Dassault Aviation has built up expertise recognized worldwide in the design, production, sale and support of all types of aircraft, ranging from the Rafale fighter, to the high-end Falcon family of business jets, military drones and space systems. In 2025, Dassault Aviation had about 15,000 employees and reported revenues of € 7.4 billion.           dassault-aviation.com

ABOUT AED CLUSTER PORTUGAL:

AED Cluster Portugal is the national association for the Aeronautics, Space and Defence industries, officially recognised by the Portuguese Government. With more than 180 members, including companies, universities and research institutes, the cluster’s mission is to promote competitiveness and sustainable growth across these strategic sectors. Through cooperation, innovation and internationalisation initiatives, AED Cluster Portugal works to strengthen the country’s position in global value chains and contribute to national economic development.

PRESS CONTACTS:

DASSAULT AVIATION

Corporate Communications        
Stéphane Fort +33 (0)1 47 11 86 90 – stephane.fort@dassault-aviation.com
Mathieu Durand +33 (0)1 47 11 85 88 – mathieu.durand@dassault-aviation.com

RAFALE Communications
Nathalie Bakhos +33 (0)1 47 11 84 12 – nathalie-beatrice.bakhos@dassault-aviation.com

HD photos: mediaprophoto.dassault-aviation.com

HD videos: mediaprovideo.dassault-aviation.com

AED CLUSTER PORTUGAL

Communication and Marketing
Márcia Campana +351 938 840 820 – marcia.campana@aedportugal.pt

Attachment

• PR_Dassault Aviation_AED MOU OK

Vancouver, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — It is with deep sadness that NevGold Corp. (“NevGold” or the “Company”) announces the passing of Tim Dyhr, a long-standing member of the Company’s Board of Directors and a valued friend and business colleague. On behalf of the Board of Directors, management and employees of NevGold, we extend our deepest condolences to Carol, Tim’s family, loved ones, and all of those who had the privilege of knowing him.

Tim was a highly respected founding member of the NevGold Board and a tremendous contributor to the Company over many years. His insight, judgment, experience, and commitment were deeply valued, and his contributions extended well beyond the boardroom. Tim led multidisciplinary teams to successfully permit over twelve copper and gold mines in Nevada, Arizona, California, Washington, Montana, Wyoming, Peru, while also working on mining projects in Chile, Argentina, Australia, Africa, Turkey, China, and Papua New Guinea. In 2015 Tim successfully led the Congressional conveyance of over 10,000 acres of BLM-administered federal lands to the Pumpkin Hollow Project in Nevada (owned by Nevada Copper Corp. at the time), the only successful privatization of federal lands for mining in Nevada in the past 30 years.

More importantly, Tim was simply an exceptional individual. He was admired not only for his many professional accomplishments, but also for his character, integrity, generosity and genuine regard for the people around him. He built lasting relationships with colleagues, business partners and friends, and his presence had a meaningful impact on all who had the privilege of knowing him.

Giulio Bonifacio, Chair, comments: “Tim was a very special person to all of us at NevGold. He brought tremendous experience, wisdom and perspective to our Board, but what we will remember most is the person. He was thoughtful, and a trusted colleague and, to many of us, a very dear friend. We are deeply saddened by his passing and will miss him greatly.”

Brandon Bonifacio, CEO, comments: “We are deeply saddened by the passing of Tim. Tim acted not only as a mentor, but as a friend and colleague. He was instrumental to the Company, and he will be greatly missed as we continue to advance NevGold. His legacy will remain and he will be in our thoughts as we execute and deliver on what we have set out to do.”

The Company will take the necessary steps to address the vacancy and consider the appropriate process for identifying and appointing a new director and will provide further information as appropriate.

About the Company
NevGold is dedicated to discovering, de-risking, and rapidly advancing gold and critical metals projects across premier jurisdictions in Nevada and Idaho to drive shareholder value and strengthen US mineral security. The Company holds a 100% interest in the Limousine Butte (gold-antimony) and Cedar Wash (gold) projects in Nevada, and the Nutmeg Mountain (gold) and Zeus (copper) projects in Idaho. For more information, please visit www.nev-gold.com.

ON BEHALF OF THE BOARD
“Signed”

Brandon Bonifacio, President & CEO

For further information, please contact Brandon Bonifacio at bbonifacio@nev-gold.com, call 604-337-5033, or visit our website at www.nev-gold.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.